An Everest Group report analyzed operations of 24 service providers specific to the life sciences sector globally; TCS was positioned highest for vision and capability. The company’s significant scale in the LS operations services market, with solutions like its cloud-based Advanced Drug Development suite of platforms witnessing increased traction in the market, particularly the Connected Clinical Trials module, which enables patient engagement and clinical supply process visibility, have been cited as key strengths. The report highlights that TCS is deploying automation for multiple customers in pharmacovigilance, data management, and the medical affairs segments, which is augmented by its in-house technology engine — the TCS Decision Fabric.
“The life sciences industry is under tremendous pressure to streamline processes, comply with regulatory norms, launch newer drugs at a faster pace, and deliver real value for patients. Under the weight of such issues, the core capability of a pharma company – innovation – can often take a back seat,” says Manu Aggarwal, Vice President, Everest Group. “TCS’ investments in creating an integrated platform – the Advanced Drug Development (TCS ADD) platform – along with focus on building deep domain expertise and expansion into newer services such as commercialization is bringing the focus back on drug innovation.”
TCS was positioned as a Star Performer for its addition of new customers in the clinical trials and regulatory affairs value chain segments, and investments in building solutions and its talent pool to expand into newer processes such as commercial operations and supply chain.